Last reviewed · How we verify
NCT04353154
The RAPID COVID-19 TRIAGE Algorithm
trial testing Spartan Cube Point-of Care Covid-19 test in COVID-19 in 66 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2025
Quick facts
| Lead sponsor | Ottawa Heart Institute Research Corporation |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 66 |
| Start date | 15 June 2020 |
| Primary completion | 31 March 2025 |
| Estimated completion | 28 June 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Spartan Cube Point-of Care Covid-19 test
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Ottawa Heart Institute Research Corporation
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being conducted to study the use and application of a point-of-care (POC) Covid-19 test developed by Spartan BioSciences and recently approved for clinical use by Health Canada. Phase I of this study will determine the best route for the swabs (nasal, throat, or both), and to determine if this POC test results are comparable to the standard core-lab test results.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04353154
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Ottawa Heart Institute Research Corporation trials
Trials by the same sponsor.
- NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
- NCT07002450 — Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Departm · NA · recruiting
- NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
- NCT06556667 — MAX - SHOCK Clinical Trial · NA · recruiting
- NCT06816888 — Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04353154 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04353154.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing